United Kingdom · Investor

Janus Henderson Investors

Last cheque observed Oct 2026; 178 cheques on record.

Deploying nowPrivate equity

SeedSeries ASeries BCreditPaymentsAsset Management

Deploying now
90%of best year79cheques in 12 months, 178 on record
Since the last cheque8days00hrs00min00sec
Median round$115MRounds led2 of 178Sole investor4 roundsMostly inUnited States, 85%
Pitch Janus Henderson Investors

Janus Henderson Investors highlights

  1. 01

    79 cheques in the last 12 months

  2. 02

    Mostly Series B and Series C: 60% of its rounds

  3. 03

    Sole investor in 4 rounds, median $33M

What they do

We provide access to some of the industry’s most talented and innovative thinkers.From their own website
Type
Private equity (from a list, unverified)
Cheque size
Not stated
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
CreditPaymentsAsset Management
Based in
London, United Kingdom
Cold pitches
Not stated

The record

Every round we can evidence, newest first178 appearances

  1. 2026

    63 rounds

  2. Oct
  3. Oct
    OMass TherapeuticsSeries C · GB · Jefferson Life Sciences$310MWith 12 others
  4. Oct
  5. Sept
    Tyra BiosciencesUS$400MWith 5 others
  6. Sept
    Pyxis OncologyUS$110MWith 4 others
  7. Sept
    TareSeed · US$13MWith 2 others
  8. Sept
    AN2 TherapeuticsGrant · US$40MWith 4 others
  9. Sept
    Encoded TherapeuticsSeries F · US$275MWith 4 others
  10. Sept
    Helus PharmaCA$50MWith 3 others
  11. Aug
    Epicrispr BiotechnologiesSeries C · US$90MWith 3 others
  12. Jul
    Annexon BiosciencesDebt · US$50MWith 3 others
  13. Jul
    Claris BiotherapeuticsSeries B · US$118MWith 4 others
  14. Jul
    WallboxES$4.6MWith 3 others
  15. Jul
    Draig TherapeuticsSeries B · GB · Jefferson Life Sciences$65MWith 6 others
  16. Jul
    NeurogeneUS$125MWith 4 others
  17. Jun
    Element BiosciencesGrowth · US · Ventureburn$175MWith 4 others
  18. Jun
    Tango TherapeuticsUS$600MWith 2 others
  19. Jun
    Lycia TherapeuticsSeries D · US$75MWith 3 others
  20. Jun
    ALX OncologyDebt · US$10MWith 4 others
  21. Jun
    Definium TherapeuticsUS$805MWith 1 other
  22. Jun
    Entact BioVenture · US$10MWith 2 others
  23. Jun
    Oak hill bioSeries A · GB$33MSole investor
  24. Jun
    Jade BiosciencesUS$150MWith 4 others
  25. Jun
    SmartMedia TechnologiesVenture · USUndisclosedSole investor
  26. Jun
    Parabilis MedicinesUS$75MWith 4 others
  27. Jun
    4D Molecular TherapeuticsDebt · US$200MWith 3 others
  28. Jun
    Shattuck LabsUS$75MWith 4 others
  29. Jun
    Triveni BioSeries C · US$65MWith 4 others
  30. Jun
    Enliven TherapeuticsUS$460MWith 3 others
  31. May
    Circle Internet GroupUS · TechStartups$222MWith 12 others
  32. May
    OcugenDebt · US$115MWith 1 other
  33. May
    Starlab SpaceVenture · USUndisclosedWith 2 others
  34. May
    Everest MedicinesSecondary · US$6.8MWith 3 others
  35. May
    Windward BioSeries B · CH$165MWith 4 others
  36. May
    Artiva BiotherapeuticsUS$300MWith 3 others
  37. Apr
    Ray TherapeuticsSeries B · US · 4BIO Capital$125MLed
  38. Apr
    CalyxoSeries F · US$40MSole investor
  39. Apr
    Maze TherapeuticsUS$150MWith 5 others
  40. Apr
    Climb BioUS$110MWith 4 others
  41. Apr
    Forte BiosciencesUS$150MWith 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration13 named

BTBarbara TarbelChief Financial Officer and Board MemberiForm ADV
BABerg Ashton CrawfordChief Accounting OfficeriForm ADV
DJDan James SuzukiDeputy Chief Investment Officer & Chairman of the Investment CommitteeiForm ADV
FMFrank Matthew GriswoldDirector of Investments and Risk ManagementiForm ADV
JJJohn Joseph MccombePresident, Director of Distribution and Board MemberiForm ADV
JRJohn Raymond ReaganChief Technology OfficeriForm ADV
KBKristin Brett MarianiChief Compliance OfficeriForm ADV
LKLisa KirschnerDirector of ResearchiForm ADV
MAMichael Alan SchweitzerHead of North America Client GroupiForm ADV
MHMichael Harris MeyerChief Compliance OfficeriForm ADV
MRMichelle Rose RosenbergPresident and General CounseliForm ADV
PSPhilip Stephen GoldfarbDirector of TradingiForm ADV
RBRichard BernsteinChief Executive Officer, Chief Investment Officer, Board Member and MemberiForm ADV

We also hold 27 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

$381Bassets it manages, 2 advisers combinedOct 2026
Registeredinvestment adviserfull reporting to the SEC
Legal name
Richard Bernstein Advisors LLC
SEC number
CRD 153577

Funds on its Form ADV

12 private funds, $6.7B in gross assets · filed Nov 2024

Hedge 6Liquidity 2Long only equity 2

  1. Janus Henderson Cash Liquidity Fund LLCLiquidity47 investors$3.4B
  2. Janus Henderson Biotech Innovation Master Fund LTD.Hedge148 investors$820M
  3. Janus Henderson Core Plus Fixed Income Fund LLCLong only fixed income4 investors$648M
  4. Janus Henderson Multi-Strategy Master Fund LTD.Hedge36 investors$524M
  5. Janus Henderson European Best Ideas Fund LLCCommingled fund partnership175 investors$311M
  6. Janus Henderson Biotech Innovation Master Fund II LTD.Hedge2 investors$228M
  7. Janus Henderson Cash Collateral Fund LLCLiquidity41 investors$183M
  8. Janus Henderson International Research Equity PortfolioLong only equity6 investors$166M
  9. Janus Henderson Castor Master Fund LTD.Hedge9 investors$154M
  10. Janus Henderson Dynamic Trend Master Fund LTD.Hedge1 investor$107M

And 2 more on the filing.

Who they invest alongside

The investors most often in the same rounds as Janus Henderson Investors. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Janus Henderson Investors put money into.

On podcasts

2 episodes naming Janus Henderson Investors in the title, and 3 more that mention it.

Mentioned in

Quick answers about Janus Henderson Investors

What does Janus Henderson Investors invest in?

Janus Henderson Investors invests most often at Series B and Series C (60% of the rounds on record), in sectors such as Credit, Payments and Asset Management.

How active is Janus Henderson Investors?

178 investments on record, 79 of them in the last 12 months, and it led 2. The most recent was in Oct 2026.

What has Janus Henderson Investors invested in recently?

Its most recent investments on record: Star Therapeutics (Undisclosed round, Oct 2026), OMass Therapeutics (Series C, Oct 2026) and Alaunos Therapeutics (Undisclosed round, Oct 2026).

How big are Janus Henderson Investors's cheques?

The median round it joins is $115M.

Does Janus Henderson Investors lead rounds?

Sometimes: it led 2 of its 178 investments on record (1%).

Where does Janus Henderson Investors invest?

Most of the companies it backs are in the United States (85%) and the United Kingdom (8%).

Is Janus Henderson Investors investing now?

Yes: it is actively investing, with 79 investments in the last 12 months.

Who does Janus Henderson Investors invest alongside?

Most often RA Capital Management (68 rounds together), Cormorant Asset Management (39 rounds together) and Wellington Management (30 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it